Clinical, toxicological and pharmaceutical aspects of the antineoplastic drug taxol: A review

Guchelaar, H. J.; Napel, C.H.H. ten; Vries, Elisabeth G.E. de; Mulder, Nanno

doi:10.1016/s0936-6555(05)80367-x

Cited by 61 publications

(27 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is expected that paclitaxel may have caused a brief and mild epithelial injury in our rat model due to the frequent gastrointestinal toxicity which has been observed in patients treated with paclitaxel-based chemotherapy regimens. 24,25 In addition, a single injection of intraperitoneal paclitaxel has been shown to induce epithelial apoptosis, loss of mucosal structure and bacterial translocation in rats, 26 albeit at a higher dose than that used in this study. However, further research is required to unequivocally confirm histological injury in our model.…”

Section: Discussionmentioning

confidence: 83%

Development of a rat model of oral small molecule receptor tyrosine kinase inhibitor-induced diarrhea

Bowen

Mayo

Plews

et al. 2012

Cancer Biology & Therapy

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 83%

Development of a rat model of oral small molecule receptor tyrosine kinase inhibitor-induced diarrhea

Bowen

Mayo

Plews

et al. 2012

Cancer Biology & Therapy

View full text Add to dashboard Cite

“…Like tub2-150 cells under nonpermissive conditions, tissue culture cells treated with taxol fail to complete mitosis (Jordan et al, 1993). Taxol is an effective chemotherapeutic agent against a number of different aggressive cancers (Guchelaar et al, 1994). As taxol does not affect S. cerevisiae microtubules (Barnes et al, 1992), the genetic, molecular, and biochemical characterization of tub2-150 microtubules may offer unique insights into the mode of action of this important drug.…”

Section: Discussionmentioning

confidence: 99%

Microtubule stability in budding yeast: characterization and dosage suppression of a benomyl-dependent tubulin mutant.

Machin

Lee

Barnes

1995

MBoC

View full text Add to dashboard Cite

To better understand the dynamic regulation of microtubule structures in yeast, we studied a conditional-lethal ,B-tubulin mutation tub2-150. This mutation is unique among the hundreds of tubulin mutations isolated in Saccharomyces cerevisiae in that it appears to cause an increase in the stability of microtubules. We report here that this allele is a mutation of threonine 238 to alanine, and that tub2-150 prevents the spindle from elongating during anaphase, suggesting a nuclear microtubule defect. To identify regulators of microtubule stability and/or anaphase, yeast genes were selected that, when overexpressed, could suppress the tub2-150 temperature-sensitive phenotype. One of these genes, JSNI, encodes a protein of 125 kDa that has limited similarity to a number of proteins of unknown function. Overexpression of the JSNI gene in a TUB2 strain causes that strain to become more sensitive to benomyl, a microtubule-destabilizing drug. Of a representative group of microtubule mutants, only one other mutation, tub2-404, could be suppressed by JSNI overexpression, showing that JSNI is an allelespecific suppressor. As tub2-404 mutants are also defective for spindle elongation, this provides additional support for a role for JSNI during anaphase.

show abstract

“…Paclitaxel is a taxane, a group of commonly structured compounds found in various members of the yew family. Studies have shown that paclitaxel promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules, blocking depolymerization (10). By stabilizing microtubules, paclitaxel interferes with the normal microtubule network dynamics of living cells, especially spindle apparatus formation during mitosis, forming microtubule arrays and multiple asters of microtubules, thereby halting cell division in the G 2 -M phase, the most radiosensitive phase (11,12).…”

mentioning

confidence: 99%

Does Paclitaxel (Taxol) Given after 111In-Labeled Monoclonal Antibodies Increase Tumor-Cumulated Activity in Epithelial Cancers?

Miers

Lamborn

Yuan

et al. 2005

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: Paclitaxel synergized radiolabeled monoclonal antibodies, enhancing therapeutic effect in studies in mice with human xenografts. Paclitaxel was also observed to increase tumor uptake in imaging studies of 111 In-DOTA-Gly 3 Phe-m170 in patients with breast and prostate cancers. Further evaluations of tissue-cumulated activities, therapeutic indices, and pharmacokinetics were done using data for patients with breast and prostate cancer and for mice with human breast cancer xenografts. Experimental Design: In radioimmunotherapy trials, 12 patients with breast or prostate cancer were given two imaging doses (5 mCi each) of In. In a subsequent study, athymic mice with human breast cancer xenografts were given 111In-DOTA-Gly 3 Phe-ChL6 alone, or in combination with daily paclitaxel i.p. (300 Ag) one or more times. Pharmacokinetics were studied for at least 6 days in patients and 5 days in mice. Cumulated activities were determined for tumors and normal tissues. Results: Tumor-cumulated activity for every patient in the paclitaxel-treated group increased for the second dose of In-DOTA-Gly 3 Phe-m170. The median ratio of cumulated activities in tumors for imaging dose 2 to those for dose 1was 1.0 (0.8-1.3) in patients that were not given paclitaxel and 1.3 (1.2-1.4) in patients given paclitaxel. Normal tissue-cumulated activities were not different for the two doses. Mice given paclitaxel 1 day after 111

show abstract

Clinical, toxicological and pharmaceutical aspects of the antineoplastic drug taxol: A review

Cited by 61 publications

References 46 publications

Development of a rat model of oral small molecule receptor tyrosine kinase inhibitor-induced diarrhea

Development of a rat model of oral small molecule receptor tyrosine kinase inhibitor-induced diarrhea

Microtubule stability in budding yeast: characterization and dosage suppression of a benomyl-dependent tubulin mutant.

Does Paclitaxel (Taxol) Given after 111In-Labeled Monoclonal Antibodies Increase Tumor-Cumulated Activity in Epithelial Cancers?

Contact Info

Product

Resources

About